| scholarly article | Q13442814 |
| P2093 | author name string | K J O'Byrne | |
| J G Edwards | |||
| T J Spyt | |||
| D A Waller | |||
| K R Abrams | |||
| J N Leverment | |||
| P2860 | cites work | Evaluation of tumour angiogenesis as a prognostic marker in malignant mesothelioma | Q73634290 |
| Syndecan-1 expression in malignant mesothelioma: correlation with cell differentiation, WT1 expression, and clinical outcome | Q77349750 | ||
| The European mesothelioma epidemic | Q24650064 | ||
| Advances in the treatment of malignant pleural mesothelioma | Q33715899 | ||
| Nucleic acid targeting: therapeutic strategies for the 21st century | Q33722395 | ||
| A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group | Q34295028 | ||
| Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma. | Q34457473 | ||
| Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients | Q34485292 | ||
| Malignant mesothelioma in south east England: clinicopathological experience of 272 cases | Q35563609 | ||
| VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. | Q36641154 | ||
| Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma | Q39447961 | ||
| Malignant pleural mesothelioma. Multivariate analysis of prognostic factors on 113 patients | Q40819089 | ||
| Diffuse malignant mesothelioma. Prospective evaluation of 69 patients | Q40844231 | ||
| The importance of surgical staging in the treatment of malignant pleural mesothelioma | Q40945772 | ||
| Continuing increase in mesothelioma mortality in Britain. | Q40991450 | ||
| Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients | Q41226875 | ||
| Survival patterns for malignant mesothelioma: the SEER experience | Q41435451 | ||
| Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience | Q41688263 | ||
| Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers | Q43751848 | ||
| Clinical features and epidemiology of malignant pleural mesothelioma in west Glasgow 1987-1992. | Q44197535 | ||
| Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. | Q44267257 | ||
| Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 2: Prognosis and staging. | Q53389026 | ||
| Surgical staging and work-up of patients with diffuse malignant pleural mesothelioma | Q64050209 | ||
| Prognostic factors in diffuse malignant pleural mesothelioma. A study of 167 patients | Q68248790 | ||
| Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1985 | Q68250517 | ||
| Randomized comparison of cyclophosphamide, imidazole carboxamide, and adriamycin versus cyclophosphamide and adriamycin in patients with advanced stage malignant mesothelioma: a Sarcoma Intergroup Study | Q68929587 | ||
| Prognostic factors of malignant mesothelioma of the pleura | Q72800457 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| P304 | page(s) | 731-5 | |
| P577 | publication date | 2000-09-01 | |
| P1433 | published in | Thorax | Q7796158 |
| P1476 | title | Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems | |
| P478 | volume | 55 |
| Q52668368 | "The Less I Think About It, the Better I Feel": A Thematic Analysis of the Subjective Experience of Malignant Mesothelioma Patients and Their Caregivers. |
| Q33414357 | A phase II trial of prolonged, continuous infusion of low-dose gemcitabine plus cisplatin in patients with advanced malignant pleural mesothelioma |
| Q47685374 | A review of bevacizumab in the treatment of malignant pleural mesothelioma |
| Q36162505 | Advances in the diagnosis, evaluation, and management of malignant pleural mesothelioma |
| Q37070229 | Advances in the systemic therapy of malignant pleural mesothelioma |
| Q36643416 | Angiogenesis is an independent prognostic factor in malignant mesothelioma |
| Q36027639 | Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio reliable parameters as prognostic indicators in malignant mesothelioma? |
| Q38408709 | BIRC5 promoter SNPs do not affect nuclear survivin expression and survival of malignant pleural mesothelioma patients |
| Q38660038 | Biomarkers and prognostic factors for malignant pleural mesothelioma |
| Q28387194 | Biomarkers and prognostic factors for mesothelioma |
| Q37335377 | Biomarkers for malignant pleural mesothelioma: current status |
| Q41086929 | Brain metastases in malignant pleural mesothelioma |
| Q39942737 | Characteristics and modifying factors of asbestos-induced oxidative DNA damage. |
| Q24648532 | Chronic immune activation and inflammation as the cause of malignancy |
| Q34554736 | Chronic immune activation and inflammation in the pathogenesis of AIDS and cancer |
| Q50050310 | Clinical and biologic prognostic factors in malignant pleural mesothelioma |
| Q36643797 | Clinical and immunological assessment of Mycobacterium vaccae (SRL172) with chemotherapy in patients with malignant mesothelioma |
| Q41522440 | Clinical staging of malignant pleural mesothelioma: current perspectives |
| Q35770196 | Comparative genomic hybridisation in malignant deciduoid mesothelioma. |
| Q28393560 | Current issues in malignant pleural mesothelioma evaluation and management |
| Q50491668 | Deciduoid mesothelioma in the pelvic cavity. |
| Q40250383 | Detection of malignant mesothelioma using nuclear structure of mesothelial cells in effusion cytology specimens |
| Q36702389 | Disease volumes as a marker for patient response in malignant pleural mesothelioma. |
| Q36694116 | Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers? |
| Q58765920 | Early-stage Clinical Characterization of Malignant Pleural Mesothelioma |
| Q88875732 | Effects of Reduction in Tumor Burden on Survival in Epithelioid Malignant Pleural Mesothelioma |
| Q36758593 | Emerging drugs for mesothelioma |
| Q46548604 | Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma |
| Q37214250 | Existing models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma |
| Q92439627 | Exposure-Response Analysis of Overall Survival for Tremelimumab in Unresectable Malignant Mesothelioma: The Confounding Effect of Disease Status |
| Q39298123 | Expression of Wilms' tumor gene (WT1) is associated with survival in malignant pleural mesothelioma. |
| Q38437441 | Expression of bcl-2 family members in malignant pleural mesothelioma |
| Q44610633 | Factors influencing long-term survival in mesothelioma patients--results of the German mesothelioma register |
| Q58566291 | Factors influencing malignant mesothelioma survival: a retrospective review of the National Mesothelioma Virtual Bank cohort |
| Q37449036 | Future developments in the management of malignant pleural mesothelioma |
| Q38989972 | Geographic and socioeconomic factors in patients with malignant pleural mesothelioma in New South Wales and their impact upon clinical outcomes |
| Q28394028 | Guidelines for the diagnosis and treatment of malignant pleural mesothelioma |
| Q40238588 | Heterogeneous nuclear ribonucleoprotein B1 expression in malignant mesothelioma |
| Q62392158 | Hyponatraemia is a predictor of clinical outcome for malignant pleural mesothelioma |
| Q33400437 | Induction chemotherapy, extrapleural pneumonectomy, and adjuvant radiotherapy for malignant pleural mesothelioma: experience of Guy's and St Thomas' hospitals |
| Q90383249 | Intramedullary Metastasis to the Cervical Spinal Cord from Malignant Pleural Mesothelioma: Review of the Literature and Case Reports |
| Q35678741 | Ki67 index is an independent prognostic factor in epithelioid but not in non-epithelioid malignant pleural mesothelioma: a multicenter study |
| Q37625318 | Life Expectancy in Pleural and Peritoneal Mesothelioma |
| Q37613240 | Making the case for molecular staging of malignant pleural mesothelioma |
| Q35623638 | Malignant Pleural Mesothelioma Outcomes in the Era of Combined Platinum and Folate Antimetabolite Chemotherapy. |
| Q82051649 | Malignant Pleural Mesothelioma: A Population-Based Study of Survival |
| Q87322726 | Malignant mesothelioma |
| Q47098675 | Malignant mesothelioma: Canadian perspective and research directions |
| Q35740408 | Malignant pleural mesothelioma--an update |
| Q40041012 | Malignant pleural mesothelioma: A retrospective analysis of clinicopathological and survival data. |
| Q59274199 | Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
| Q33871571 | Malignant pleural mesothelioma: predictors and staging |
| Q38308730 | Matrix metalloproteinases 2 and 9 (gelatinases A and B) expression in malignant mesothelioma and benign pleura |
| Q35885161 | Mesothelial cell proliferation and apoptosis |
| Q37201356 | Mesothelioma and asbestos-related pleural diseases |
| Q42548512 | Microenvironment-Dependent Phenotypic Changes in a SCID Mouse Model for Malignant Mesothelioma |
| Q29248127 | Modern management of malignant pleural mesothelioma |
| Q35832918 | NF2 blocks Snail-mediated p53 suppression in mesothelioma. |
| Q26859274 | New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas |
| Q36780582 | Newer issues in mesothelioma chemotherapy. |
| Q36905239 | Optimising survival in malignant mesothelioma |
| Q33871599 | Overview of treatment related complications in malignant pleural mesothelioma |
| Q49389798 | Patterns of care and survival among patients with malignant mesothelioma in the United States |
| Q39831596 | Phenotype-dependent apoptosis signalling in mesothelioma cells after selenite exposure |
| Q36287976 | Post-chemotherapy T-cell recovery is a marker of improved survival in patients with advanced thoracic malignancies |
| Q36075313 | Prognosis and prognostic factors of patients with mesothelioma: a population-based study |
| Q42922993 | Prognostic Factors for Survival after Surgical Palliation of Malignant Pleural Effusion |
| Q43875251 | Prognostic nutritional index predicts outcomes of malignant pleural mesothelioma |
| Q45020726 | Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma. |
| Q42745414 | Radical surgery for mesothelioma |
| Q36425940 | Ranpirnase--an antitumour ribonuclease: its potential role in malignant mesothelioma |
| Q51757335 | Relation between neutrophil/lymphocyte ratio and primary tumor metabolic activity in patients with malign pleural mesothelioma. |
| Q34680445 | Reliability of Family Proxy Data for Studies of Malignant Mesothelioma: Results from the ATSDR Pilot Surveillance |
| Q42864235 | Second-line therapy in patients with malignant pleural mesothelioma. A French retrospective study (2005-2006) |
| Q51708886 | Serum albumin as a significant prognostic factor in patients with malignant pleural mesothelioma. |
| Q59796596 | Simultaneous presence of lung adenocarcinoma and malignant pleural mesothelioma: A case report |
| Q37582256 | Small bowel metastasis from pancreatic cancer in a long-term survival patient with synchronous advanced malignant pleural mesothelioma: A case report and literature review |
| Q44080402 | Stratification of malignant pleural mesothelioma prognosis using recursive partitioning analysis |
| Q34041728 | Supplementary prognostic variables for pleural mesothelioma: a report from the IASLC staging committee. |
| Q53733133 | Survival and Prognostic Factors in Malignant Pleural Mesothelioma: A Retrospective Study of 314 patients in the West Part of Japan |
| Q50286398 | Survival prediction in mesothelioma using a scalable Lasso regression model: instructions for use and initial performance using clinical predictors. |
| Q41376845 | The challenge of prognostic markers in pleural mesothelioma |
| Q53320850 | Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma. |
| Q79267484 | Tumor Necrosis Correlates With Angiogenesis and Is a Predictor of Poor Prognosis in Malignant Mesothelioma * |
| Q37208731 | Validation of EORTC and CALGB prognostic models in surgical patients submitted to diagnostic, palliative or curative surgery for malignant pleural mesothelioma. |
| Q89754491 | Video assisted thoracoscopic and open chest surgery in diagnosis and treatment of malignant pleural diseases |
| Q39211278 | Video-assisted cervical thoracoscopy: a novel approach for diagnosis, staging and pleurodesis of malignant pleural mesothelioma |
| Q37128016 | Which type of surgery should become the preferred procedure for malignant pleural mesothelioma: extrapleural pneumonectomy or extended pleurectomy? |
| Q80426618 | [Malignant pleural mesothelioma: interrogations and hopes concerning the expected epidemic] |
Search more.